PeproMene Bio
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
15375 Barranca Pkwy Ste A211, Irvine, Ca...Phone Number
(949) 418-8860Website
www.pepromenebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About PeproMene Bio
PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. The company is committed to developing novel therapies to treat cancers and immune disorders. The company's BAFFR CAR-T therapy program is based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwaks team at MD Anderson Cancer Center, Houston, Texas, and City of Hope National Medical Center, Duarte, California.Explore more
PeproMene Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PeproMene Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
PeproMene Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when PeproMene Bio launches new products
Earning: See what the market has to say on PeproMene Bio recently announced quarterly report
Click to see if PeproMene Bio had a recent Job posting/layoffs
Check out if PeproMene Bio is spiking on competitors!
Funding: Get notified immidiatlly once PeproMene Bio has new funding data
Check if PeproMene Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at PeproMene Bio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined PeproMene Bio as Masked Content
Find more new buyers
Compare Similar Companies to PeproMene Bio
Compare insights from companies similar to PeproMene Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PeproMene Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PeproMene Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PeproMene Bio.
PeproMene Bio financials insights
Gather financial insights about PeproMene Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$11M
PeproMene Bio Tech Stack
A closer look at the technologies used by PeproMene Bio
See more technologies
PeproMene Bio News & Media
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral...PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been...PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been...PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma
Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive $6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. Patients with relapsed/refractory follicular lymphoma will be included in the expansion phase of PeproMene Bio's PMB-102 Phase 1 study evaluating BAFF-R targeting CAR T cells (PMB-CT01) in adult patients with r/r B-cell Non-Hodgkin Lymphoma (B-NHL). IRVINE, Cali
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PeproMene Bio
Sign Up For FreeTo access detailed company insights
PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. The company is committed to developing novel therapies to treat cancers and immune disorders. The company's BAFFR CAR-T therapy program is based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwaks team at MD Anderson... Read More
